4.3 Review

Lipidomics and Biomarker Discovery in Kidney Disease

期刊

SEMINARS IN NEPHROLOGY
卷 38, 期 2, 页码 127-141

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semnephrol.2018.01.004

关键词

Lipidomics; biomarkers; mass spectrometry; metabolomics

资金

  1. National Institutes of Health [K08DK106523, P30DK089503, DK082841, P30DK081943, P30DK020572, DK097153]
  2. Clinical and Translational Science Award (CTSA) by Michigan Institute for Clinical and Health Research (MICHR) [UL1TR000433]

向作者/读者索取更多资源

Technological advances in mass spectrometrybased lipidomic platforms have provided the opportunity for comprehensive profiling of lipids in biological samples and shown alterations in the lipidome that occur in metabolic disorders. A lipidomic approach serves as a powerful tool for biomarker discovery and gaining insight to molecular mechanisms of disease, especially when integrated with other -omics platforms (ie, transcriptomics, proteomics, and metabolomics) in the context of systems biology. In this review, we describe the workflow commonly applied to the conduct of lipidomic studies including important aspects of study design, sample preparation, biomarker identification and quantification, and data processing and analysis, as well as crucial considerations in clinical applications. We also review some recent studies of the application of lipidomic platforms that highlight the potential of lipid biomarkers and add to our understanding of the molecular basis of kidney disease. (C) 2018 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据